In this expert Q&A, Margaret A. Lampe, RN, MsC, discusses the elimination of perinatal HIV transmission, elimination goals set out by the CDC, next steps for research, and more.
In this expert Q&A, Margaret A. Lampe, RN, MsC, discusses the elimination of perinatal HIV transmission, elimination goals set out by the CDC, next steps for research, and more.
In this expert Q&A, Margaret A. Lampe, RN, MsC, discusses the elimination of perinatal HIV transmission, elimination goals set out by the CDC, next steps for research, and more.
In this expert Q&A, Margaret A. Lampe, RN, MsC, discusses the elimination of perinatal HIV transmission, elimination goals set out by the CDC, next steps for research, and more.
In this Q&A, Brittany A. Davidson, MD, discusses navigating goals-of-care conversations in gynecologic oncology, including how to identify patients at high risk of death who might benefit from a timely...
In this Q&A, Brittany A. Davidson, MD, discusses navigating goals-of-care conversations in gynecologic oncology, including how to identify patients at high risk of death who might benefit from a timely...
In this interview, Elmar Joura, MD, answers questions about the long-term follow-up data on sustained immunogenicity and safety for the 9-valent human papillomavirus (HPV) vaccine, including indications,...
In this interview, Elmar Joura, MD, answers questions about the long-term follow-up data on sustained immunogenicity and safety for the 9-valent human papillomavirus (HPV) vaccine, including indications,...
In this interview, Elmar Joura, MD, answers questions about the long-term follow-up data on sustained immunogenicity and safety for the 9-valent human papillomavirus (HPV) vaccine, including indications,...
In this interview, Elmar Joura, MD, answers questions about the long-term follow-up data on sustained immunogenicity and safety for the 9-valent human papillomavirus (HPV) vaccine, including indications,...
